new med for type 2 diabetes, Avandia (rosiglitazone)

There's now a new med for type 2 diabetes, Avandia (rosiglitazone)...from SmithKline Beecham.

It's the first "glitazone" to hit the market in Canada. Rezulin (troglitazone) was approved but never marketed in Canada. Another glitazone, Actos (pioglitazone), is due later this year.

These drugs reduce insulin resistance by stimulating the uptake of glucose into skeletal muscle cells...and decreasing glucose production in the liver.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote